RankAlpha logo
Back to Rankings

KURA

Kura OncologyD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
KOMZIFTI has early commercial traction and broad payer access, while ziftomenib's AML combination programs and darlifarnib's FIT-001 development provide multiple potential clinical value inflections. The primary-source operating evidence is constructive, but the Q2 follow-up remains unconfirmed.
Posture
Defensive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-10-29.
What can break
Biopharma valuation is highly event-driven; disappointing data or delayed milestones could cause a sharp price decline.
Momentum
23
Value
41
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.00 · Bull $18.00 · Bear $6.00Analysis 2026-08-04; returns require an exact persisted reference.
Earnings
2026-10-29
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-26

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions

Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $31.85
Why
Momentum23 · Δ7d -12.3
Value41 · Δ7d -0.0
Sentiment64 · Δ7d -9.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-10-29.
  • • Sentiment remains the lead driver in the composite, 7D delta -9.4.

Contradictions & invalidation

  • • Biopharma valuation is highly event-driven; disappointing data or delayed milestones could cause a sharp price decline.
  • • Early KOMZIFTI revenue and prescription activity may not yet demonstrate durable commercial scale or repeat utilization.
  • • The investment case remains dependent on clinical execution, enrollment, durability of commercial uptake, and future readouts.

Catalyst clock

2026-10-29

FIT-001 darlifarnib/cabozantinib follow-up supports pipeline optionality

Lead driver: Sentiment · See AI snapshot
Momentum
23
8% active weight
Current posture
7d trendFlat
Δ7d
-12.3
Δ21d
-34.2
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
64
45% active weight
Current posture
7d trendSoftening
Δ7d
-9.4
Δ21d
+2.6
Why this grade

Composite grade D. Momentum 22.9 / Value 40.6 / Sentiment 63.5

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-04. Scenario method

B+
Bull case
20%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$855.8M
Beta
0.24
Shares Out
88.96M
P/E (TTM) · Derived
-3.0
P/S (TTM)
7.98
P/FCF (TTM)
9.99
Rev YoY
+36.5%
EPS YoY
+1.9%
Gross Margin
+97.6%
Op Margin
-411.9%
Net Debt
-$646.78M
Current Ratio
4.73
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data